Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032

This “Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032” report provides comprehensive insights about pemetrexed + cisplatin for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the pemetrexed + cisplatin for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the pemetrexed + cisplatin for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the pemetrexed + cisplatin market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary

The combination of cisplatin and pemetrexed is considered the standard of care front line regimen for malignant pleural mesothelioma (MPM). Several phase II trials demonstrated comparable response and survival rates with the use of gemcitabine and cisplatin. Few retrospective studies have compared the two regimens and with conflicting results. However, no prospective clinical trial has compared them directly.

Pemetrexed 500 mg/m2 was approved in combination with cisplatin 75 mg/m2 for the treatment of unresectable MPM. The FDA also recommended that patients begin supplementation with folate 350-1000 μg daily and vitamin B12 1,000 mcg intramuscular every 9 weeks, 3 weeks prior to pemetrexed therapy.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the pemetrexed + cisplatin description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on pemetrexed + cisplatin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the pemetrexed + cisplatin research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around pemetrexed + cisplatin.
• The report contains forecasted sales of pemetrexed + cisplatin for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for pemetrexed + cisplatin in MPM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pemetrexed + cisplatin Analytical Perspective

In-depth Pemetrexed + cisplatin Market Assessment

This report provides a detailed market assessment of pemetrexed + cisplatin for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Pemetrexed + cisplatin Clinical Assessment

The report provides the clinical trials information of pemetrexed + cisplatin for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence pemetrexed + cisplatin dominance.
• Other emerging products for MPM are expected to give tough market competition to pemetrexed + cisplatin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of pemetrexed + cisplatin in MPM.
• This in-depth analysis of the forecasted sales data of pemetrexed + cisplatin from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the pemetrexed + cisplatin in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of pemetrexed + cisplatin?
• What is the clinical trial status of the study related to pemetrexed + cisplatin in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the pemetrexed + cisplatin development?
• What are the key designations that have been granted to pemetrexed + cisplatin for MPM?
• What is the forecasted market scenario of pemetrexed + cisplatin for MPM?
• What are the forecasted sales of pemetrexed + cisplatin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to pemetrexed + cisplatin for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?

This product will be delivered within 2 business days.